| Literature DB >> 35579895 |
Lydia W Y Fung1,2, Jiaxi Zhao1,3, Vincent K C Yan1, Joseph E Blais1, Jacky C H Chan1, Silvia T H Li1, Jessica J P Shami1, Christine Kwan1,2,4, Yue Wei1, Carlos K H Wong1,2,5, Xue Li1,2,6, Celine S L Chui2,7,8, Eric Y F Wan1,2,5, Francisco T T Lai1,2, Samson Tse9, Benjamin J Cowling2,8, Ian C K Wong1,2,10, Esther W Chan1,2.
Abstract
Importance: COVID-19 has required universities to rapidly develop vaccination policies for students and staff, yet little is known about the preferences of these individuals toward vaccination. Objective: To quantify student and staff preferences for COVID-19 vaccination at a university in Hong Kong. Design, Setting, and Participants: A cross-sectional online survey study was conducted from July 20 to September 21, 2021, before the announcement of a campus-wide vaccine mandate. A survey of 42 451 eligible university students and staff used discrete-choice experiment methods to quantify 7 attributes of COVID-19 vaccination: risk of a mild or moderate adverse event after vaccination, risk of a severe adverse event after vaccination, efficacy against COVID-19 infection, efficacy against severe manifestation of COVID-19 infection, duration of protection after vaccination, incentive for completing vaccination, and out-of-pocket costs. Main Outcomes and Measures: A mixed logit regression model was used to estimate the preferences of attributes for COVID-19 vaccines and marginal willingness to pay (mWTP) adjusted for background characteristics, role, vaccination, and COVID-19 infection status of family or friends, adverse event status after vaccination among family and friends of participants, and scenario block.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35579895 PMCID: PMC9115609 DOI: 10.1001/jamanetworkopen.2022.12681
Source DB: PubMed Journal: JAMA Netw Open ISSN: 2574-3805
Characteristics of Participants
| Characteristic | No. (%) |
|---|---|
| Total participants | 3423 |
| Age, mean (SD), y | 27.1 (9.9) |
| Sex | |
| Male | 1370 (40.0) |
| Female | 2053 (60.0) |
| Place of origin | |
| Hong Kong | 2461 (71.9) |
| Other cities in mainland China | 530 (15.5) |
| India | 61 (1.8) |
| South Korea | 41 (1.2) |
| US | 34 (1.0) |
| Malaysia | 32 (0.9) |
| Other | 264 (7.7) |
| Faculty | |
| Medicine | 1010 (29.5) |
| Science | 379 (11.1) |
| Social sciences | 355 (10.4) |
| Engineering | 343 (10.0) |
| Arts | 273 (8.0) |
| Business and economics | 271 (7.9) |
| Education | 267 (7.8) |
| Law | 163 (4.8) |
| Architecture | 94 (2.7) |
| Dentistry | 86 (2.5) |
| Other | 182 (5.3) |
| Student | 2506 (73.2) |
| Staff | 917 (26.8) |
| Administration | 361 (39.4) |
| Research | 285 (31.1) |
| Technical | 91 (9.9) |
| Nonprofessoriate teaching | 87 (9.5) |
| Professoriate | 71 (7.7) |
| Other academic | 16 (1.7) |
| Clinical | 6 (0.7) |
| Self-reported health conditions | |
| Mental health disorder | 154 (4.5) |
| Autoimmune disease | 54 (1.6) |
| Heart disease | 29 (0.8) |
| Tumor (both benign and malignant) | 23 (0.7) |
| Rheumatoid arthritis | 18 (0.5) |
| Inflammatory bowel disease | 16 (0.5) |
| Kidney disease | 11 (0.3) |
| Respiratory disease | 10 (0.3) |
| COVID-19 vaccination and infection status of friends and family | |
| Family members have received the COVID-19 vaccine | 2862 (83.6) |
| Family members or friends have contracted COVID-19 | 1062 (31.0) |
| Family members or friends have experienced a severe adverse effect from the COVID-19 vaccine | 444 (13.0) |
| Participant vaccination status | |
| Not vaccinated | 618 (18.1) |
| Vaccinated | 2805 (81.9) |
| Completed 2 doses | 2351 (82.9) |
| Received first dose, will take second dose on time | 439 (15.7) |
| Received first dose, will not take the second dose | 45 (1.6) |
| Importance of factors when considering COVID-19 vaccination, mean (SD) | |
| Responsibility as a Hong Kong resident | 2.90 (1.65) |
| Self-protection | 4.15 (1.20) |
| Peer pressure to receive vaccination | 1.62 (1.42) |
| Peer pressure not to receive vaccination | 1.38 (1.37) |
| Number of daily new COVID-19 cases | 2.60 (1.54) |
| Vaccine technology (eg, mRNA, inactivated virus) | 3.35 (1.50) |
| Vaccination leave (time off from work) | 1.75 (1.66) |
| Current member of residential halls | |
| Yes | 453 (13.2) |
| No | 2970 (86.8) |
Abbreviation: mRNA, messenger RNA.
Assessed with a 5-point Likert scale (1, least important; 5, most important).
Overall Preference and Marginal Willingness to Pay of 3334 Participants in the Main Analysis
| Attribute | Crude, β (95% CI) | Adjusted, β (95% CI) | mWTP |
|---|---|---|---|
| Cost | −0.00036 (−0.00044 to −0.00028) | −0.00047 (−0.00054 to −0.00039) | NA |
| Mild to moderate adverse events | −0.098 (−0.12 to −0.081) | −0.12 (−0.13 to −0.10) | −32.7 (−41.2 to −26.4) |
| Severe adverse events | −0.20 (−0.23 to −0.17) | −0.24 (−0.27 to −0.21) | −66.8 (−81.5 to −55.3) |
| Efficacy against COVID-19 infection | 0.25 (0.23 to 0.27) | 0.30 (0.29 to 0.32) | 84.1 (71.8 to 100.8) |
| Efficacy against severe manifestation from COVID-19 infection | 0.21 (0.19 to 0.24) | 0.25 (0.24 to 0.27) | 69.7 (59.6 to 83.7) |
| Duration of protection | 0.14 (0.13 to 0.15) | 0.17 (0.15 to 0.18) | 46 (38.6 to 56.2) |
| Incentives | |||
| Low value | 0.25 (0.18 to 0.31) | 0.19 (0.11 to 0.27) | 52.2 (31.5 to 76.0) |
| High value | 0.46 (0.37 to 0.55) | 0.25 (0.14 to 0.36) | 68.8 (37.7 to 103.7) |
| Quarantine-free travel | 0.86 (0.75 to 0.96) | 0.86 (0.72 to 0.99) | 235.9 (190.3 to 294.2) |
| Model specifications | |||
| Log likelihood | −12 582 | −12 394 | NA |
| McFadden pseudo | 0.2400 | 0.2514 | NA |
Abbreviation: mWTP, marginal willingness to pay; NA, not applicable.
All differences significant at P < .001.
Adjusted for age, sex, primary role (student/staff), vaccination status of family or friends, COVID-19 infection status of people near participants, adverse event status after vaccination of people near participants, and scenario block.
Reported in USD, 1 USD = 7.8 HKD.
Preference and mWTP of Participants Stratified by Primary Role
| Attribute | Student (n = 2435) | Staff (n = 899) | ||
|---|---|---|---|---|
| Adjusted β (95% CI) | mWTP (95% CI) | Adjusted β (95% CI) | mWTP (95% CI) | |
| Cost | −0.00050 (−0.00060 to −0.00041) | NA | −0.00033 (−0.00050 to −0.00017) | NA |
| Mild to moderate adverse events | −0.16 (−0.18 to −0.14) | −41.2 (−52.1 to −32.8) | −0.23 (−0.27 to −0.18) | −87.2 (−172.1 to −55.5) |
| Severe adverse events | −0.25 (−0.29 to −0.21) | −63.5 (−80.3 to −50.3) | −0.30 (−0.37 to −0.22) | −113.5 (−220 to −72.6) |
| Efficacy against COVID-19 infection | 0.32 (0.29 to 0.34) | 80.4 (67.3 to 98.6) | 0.38 (0.33 to 0.42) | 144.7 (96.9 to 280.5) |
| Efficacy against severe manifestation from COVID-19 infection | 0.26 (0.24 to 0.28) | 65.4 (54.9 to 79.9) | 0.31 (0.27 to 0.35) | 117.7 (79.2 to 227.3) |
| Duration of protection | 0.15 (0.14 to 0.17) | 39.4 (32.1 to 49.4) | 0.17 (0.14 to 0.19) | 64.2 (41.0 to 128.2) |
| Incentives | ||||
| Low value | 0.25 (0.15 to 0.34) | 62.4 (37.7 to 90.5) | 0.39 (0.22 to 0.55) | 148 (77.1 to 304.2) |
| High value | 0.24 (0.11 to 0.37) | 61.4 (27.8 to 99.9) | 0.16 (−0.093 to 0.40) | 59.7 (−36.5 to 187.4) |
| Quarantine-free travel | 0.78 (0.63 to 0.93) | 197.2 (149.9 to 257.2) | 0.71 (0.44 to 0.98) | 273 (150.9 to 562.3) |
| Model specifications | ||||
| Likelihood | −9059 | NA | 0.2516 | NA |
| McFadden pseudo | −3230 | NA | 0.2740 | NA |
Abbreviation: mWTP, marginal willingness to pay; NA, not applicable.
Adjusted for age, sex, primary role (student/staff), vaccination status of family or friends, COVID-19 infection status of people near participants, adverse event status after vaccination of people near participants, and scenario block.
Reported in USD, 1 USD = 7.8 HKD.
Preference and Marginal Willingness to Pay of Participants Stratified by Current Membership in Residential Halls
| Attributes | Current resident (n = 446) | Not a current resident (n = 2888) | ||
|---|---|---|---|---|
| Adjusted β (95% CI) | mWTP (95% CI) | Adjusted β (95% CI) | mWTP (95% CI) | |
| Cost | −0.00079 (−0.0010 to −0.00054) | NA | −0.00042 (−0.00050 to −0.000033) | NA |
| Mild-to-moderate adverse events | −0.16 (−0.21 to −0.10) | −25.3 (−39.2 to −15.9) | −0.18 (−0.21 to −0.16) | −56.7 (−73.3 to −45.4) |
| Severe adverse events | −0.18 (−0.28 to −0.085) | −29.7 (−52.3 to −13.6) | −0.26 (−0.30 to −0.23) | −81.4 (−104.7 to −64.6) |
| Efficacy against COVID-19 infection | 0.30 (0.24 to 0.36) | 48.6 (35.6 to 71.2) | 0.34 (0.32 to 0.37) | 105.6 (87.3 to 132.6) |
| Efficacy against severe manifestation from COVID-19 infection | 0.25 (0.21 to 0.30) | 40.8 (30.5 to 58.5) | 0.27 (0.25 to 0.29) | 84.2 (69.5 to 105.6) |
| Duration of protection | 0.14 (0.10 to 0.18) | 22.7 (15 to 35.4) | 0.16 (0.15 to 0.18) | 49.5 (40 to 63.6) |
| Incentives | ||||
| Low value | 0.21 (−0.019 to 0.44) | 34.4 (−2.9 to 75.9) | 0.32 (0.23 to 0.29) | 98.3 (68.8 to 136.3) |
| High value | 0.23 (−0.082 to 0.54) | 36.7 (−13.8 to 94.6) | 0.19 (0.064 to 0.32) | 59.2 (20.5 to 103.5) |
| Quarantine-free travel | 1.02 (0.67 to 1.39) | 165.9 (165.9 to 265.1) | 0.73 (0.59 to 0.88) | 225.5 (170.1 to 299.9) |
| Model specifications | ||||
| Log likelihood | −1784 | NA | −10 482 | NA |
| McFadden pseudo | 0.2308 | NA | 0.2637 | NA |
Abbreviation: mWTP, marginal willingness to pay.
Adjusted for age, sex, primary role (student/staff), vaccination status of family or friends, COVID-19 infection status of people near participants, adverse event status after vaccination of people near participants, and scenario block.
Reported in USD, 1 USD = 7.8 HKD.
Preference and mWTP of Participants Stratified by Self-reported History of Mental Disorder
| Attributes | Mental health disorder (n = 146) | No mental health disorder (n = 3188) | ||
|---|---|---|---|---|
| Adjusted β (95% CI) | mWTP (95% CI) | Adjusted β (95% CI) | mWTP (95% CI) | |
| Cost | −0.0053 (−0.0089 to −0.0017) | NA | −0.00045 (−0.00053 to −0.00037) | NA |
| Mild-to-moderate adverse events | −0.51 (−0.81 to −0.22) | −12.6 (−30.8 to −6.4) | −0.18 (−0.20 to −0.16) | −50.8 (−63.1 to −41.4) |
| Severe adverse events | −1.54 (−2.69 to −0.39) | −37.4 (−66.8 to −16.8) | −0.25 (−0.29 to −0.22) | −72.6 (−91.3 to −58.5) |
| Efficacy against COVID-19 infection | 1.69 (0.71 to 2.66) | 41.0 (28.6 to 71.0) | 0.32 (0.30 to 0.34) | 92.2 (77.7 to 112.9) |
| Efficacy against severe manifestation from COVID-19 infection | 1.82 (0.74 to 2.89) | 44.2 (30.6 to 75.1) | 0.26 (0.25 to 0.28) | 75.3 (63.6 to 91.4) |
| Duration of protection | 0.90 (0.31 to 1.49) | 22.1 (11.3 to 43.7) | 0.16 (0.14 to 0.17) | 44.4 (36.7 to 55.4) |
| Incentives | ||||
| Low value | 1.65 (−0.45 to 3.75) | 40 (−19.0 to 12.7) | 0.28 (0.19 to 0.36) | 79.0 (53.7 to 109.1) |
| High value | 3.73 (0.0096 to 7.45) | 90.8 (−1.41 to 173.5) | 0.22 (0.10 to 0.33) | 61.7 (28.6 to 98.3) |
| Quarantine-free travel | 7.54 (1.28 to 13.81) | 183.6 (54.4 to 335.6) | 0.75 (0.61 to 0.88) | 213.2 (166.8 to 274.4) |
| Model specifications | ||||
| Log likelihood | −474 | NA | 0.3696 | NA |
| McFadden pseudo | −11 806 | NA | 0.2530 | NA |
Abbreviation: mWTP, marginal willingness to pay.
Adjusted for age, sex, primary role (student/staff), vaccination status of family or friends, COVID-19 infection status of people near participants, adverse event status after vaccination of people near participants, and scenario block.
Reported in USD, 1 USD = 7.8 HKD.